PMN (ProMIS Neurosciences) Total Equity: $60.72 Mil (As of Mar. 2026)


PMN ProMIS Neurosciences Inc PMN
30 GF Score
Price $13.39
! 2 Warning Signs
View Full Analysis

What is ProMIS Neurosciences Total Equity?

ProMIS Neurosciences PMN +22.42% 30 Total Equity is $60.72 Mil as of Mar. 2026. GuruFocus rates PMN with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

ProMIS Neurosciences's total equity for the quarter that ended in Mar. 2026 was $60.72 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

ProMIS Neurosciences Total Equity Historical Data

* Premium members only.

The historical data trend for ProMIS Neurosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProMIS Neurosciences Total Equity Chart

ProMIS Neurosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.66 -1.35 3.75 16.49 -1.26

ProMIS Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.47 -0.38 9.19 -1.26 60.72
PMN
30GF Score
ProMIS Neurosciences Inc PMN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProMIS Neurosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

ProMIS Neurosciences's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=9.182-10.441
=-1.26

ProMIS Neurosciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=67.412-6.694
=60.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $60.72 Mil mean?
ProMIS Neurosciences (PMN) has a Total Equity of $60.72 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for ProMIS Neurosciences and its competitors.
Is ProMIS Neurosciences' Total Equity too high?
ProMIS Neurosciences' current Total Equity is $60.72 Mil. Overall, ProMIS Neurosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' Total Equity compare to BMEA and ANIX?
ProMIS Neurosciences' Total Equity of $60.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for ProMIS Neurosciences and its competitors. ProMIS Neurosciences's current Total Equity is $60.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current Total Equity of $60.72 Mil. The current Total Equity is $60.72 Mil. ProMIS Neurosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current Total Equity is $60.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProMIS Neurosciences Business Description

Other Exchanges 23J:Germany
Address 1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
30GF Score

Get the complete analysis for PMN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.39
Price